ClinicalTrials.gg
TerminatedNCT02551055Updated Sep 20, 2019Results posted

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

A Phase 1 interventional study of MLN1117 and TAK-659 in Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-20.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Why this study was terminated
Business Decision; No Safety Or Efficacy Concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).

Read the detailed description

The drug being tested in this study is called MLN1117. MLN1117 is being tested to treat people who have locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This study will look at the dose-limiting toxicity and response to treatment in participants who take MLN1117 in combination with TAK-659, alisertib, paclitaxel, or docetaxel.

The study will enroll 32 participants in the dose escalation phase (Part 1) and 118 participants in the dose expansion phase (Part 2). Participants will be assigned to 1 of the 7 treatment groups:

  • MLN1117 300 mg+Alisertib
  • MLN1117 600 mg+Alisertib
  • MLN1117 300 mg+Paclitaxel
  • MLN1117 600 mg+Paclitaxel
  • MLN1117 300 mg+TAK-659
  • MLN1117 200 mg+Docetaxel
  • MLN1117 300 mg+Docetaxel

In Part 1, the dose of MLN1117 will be increased step by step. All participants will be asked to take tablets of MLN1117 for 3 days on and 4 days off per week in 28-day treatment cycles or 21-day treatment cycles when given in combination with the other companion drugs.

This multi-center trial will be conducted in Spain and United States. The overall time to participate in this study is 10 months for Part 1 and 24 months for Part 2. Participants will make multiple visits to the clinic, and be contacted by telephone, e-mail or mail every 12 weeks for up to 6 months or 1 year after the last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.

Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.

First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1 and Part 2

  1. Is male or female aged 18 years or older at the time of consent.
  2. Has (ECOG) performance status of 0 or 1 within 14 days before enrollment.
  3. Has adequate organ and hematologic function as evidenced by the following laboratory values within 14 days before enrollment:

    • (ANC) ≥1.5x10\^9/L.
    • count ≥100x10\^9/L.
    • ≥9 g/dL (Transfusions are allowed to reach this hemoglobin level).
    • Serum creatinine ≤1.5 times the (ULN) or ≥50 mL/min either as estimated by the Cockcroft-Gault equation or based on urine collection (12 or 24 hours).
    • Total ≤1.5×ULN.
    • (AST) and Alanine aminotransferase (ALT) ≤2.5×ULN.
  4. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 1 highly effective method and 1 additional effective (barrier) method of at the same time, from the time of signing the form through 30 days after the last dose of study drug (with the exception of those participants assigned to TAK-659, for whom the duration required is 180 days), or for as long as mandated by local labeling for docetaxel and paclitaxel, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant, from the time of signing the informed consent form through 30 days after the last dose of study drug (with the exception of those participants assigned to TAK-659, for whom the duration required is 180 days), or for as long as mandated by local labeling for docetaxel and paclitaxel. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.)

    Male participants, even if surgically sterilized (ie, status postvasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug (with the exception of those participants assigned to TAK-659, for whom the duration required is 180 days), or for as long as mandated by local labeling for docetaxel and paclitaxel, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant during the entire study treatment period and through 120 days after the last dose of study drug (with the exception of those participants assigned to TAK-659, for whom the duration required is 180 days) or for as long as mandated by local labeling for docetaxel and paclitaxel. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)
  5. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  6. Has suitable venous access for the study-required blood sampling (ie, pharmacokinetic (PK) sampling, circulating tumor deoxyribonucleic acid [DNA]).

Part 1 only

  1. Has a confirmed diagnosis of advanced solid tumor, including but not limited to gastric or gastroesophageal junction adenocarcinoma.
  2. Has radiographically or clinically evaluable disease. as defined by (RECIST), Version 1.1 is not required.
  3. Is with no effective therapeutic options available.

Part 2 only

  1. Has a histologically confirmed diagnosis of or locally advanced adenocarcinoma of the stomach or gastroesophageal junction (Stage IIIb or IV according to International Union Against Cancer [UICC] tumor, node, metastases [TNM] classification, 7th edition).
  2. Has at least 1 measurable tumor lesion per RECIST Version 1.1 by radiographic techniques (computed tomography [CT] or magnetic resonance imaging [MRI]).
  3. Has receipt of 1 prior systemic chemotherapy regimen for advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction with documented progressive disease (PD).
  4. Has archived or fresh tumor samples obtained during screening sufficient for Epstein-Barr virus (EBV) testing and genotyping.

Exclusion criteria

Exclusion Criteria:

Part 1 and Part 2

  1. Has received prior systemic anticancer therapies or other agents within 2 weeks before the first administration of study drug or has failed to recover from the adverse drug effects of prior therapies (to ≤Grade 1 or to a level meeting inclusion criteria). For prior therapies with a half-life longer than 3 days, the interval must equal minimally 28 days before the first administration of study drug and the participant must have documented PD.
  2. Has radiotherapy within 14 days before enrollment.
  3. Has fasting glucose ≥130 mg/dL. Poorly controlled diabetes mellitus (glycosylated [] >7.0%). Participants with a history of transient glucose intolerance due to administration are allowed.
  4. Has received strong cytochrome P-450 (CYP) 3A4 inducers/inhibitors within 7 days before the first administration of study drug or has conditions that require the concomitant use of inducers/inhibitors during the course of the study.
  5. For TAK-659 (Cohort A) only: Is receiving treatment with medications that are known to be inhibitors or inducers of P-glycoprotein (P-gp). Baseline lipase >. Participants not fulfilling these exclusion criteria can be enrolled in other cohorts (Part 1 only).
  6. Has taken proton pump inhibitors within 7 days before the first administration of study drug or has conditions that require the concomitant use of proton pump inhibitors during the course of the study.
  7. Has signs of peripheral neuropathy ≥ National Cancer Institute (NCI CTCAE) Grade 2.
  8. Has symptomatic or brain metastases with a stable neurologic status for \<2 weeks after completion of the definitive therapy and steroids.
  9. Has systemic infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
  10. Has known or suspected (HIV) positive or surface antigen-positive status, or known or suspected active infection. Testing for these agents is not required in the absence of clinical findings or suspicion.
  11. Has known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerability of orally administered study drug, including difficulty swallowing tablets; diarrhea >Grade 1 despite supportive therapy; or prior total gastrectomy.
  12. Has comorbidities, such as uncontrolled pulmonary disease, known impaired cardiac function or clinically significant cardiac disease, active central nervous system disease, or any other condition that could compromise the participant's participation in the study.

    • Known impaired cardiac function or clinically significant cardiac disease includes: evidence of currently uncontrolled cardiovascular conditions (including arrhythmias, angina, pulmonary hypertension, acute ischemia or active conduction system abnormalities); current history of Class III or IV heart failure; acute myocardial infarction within 6 months before starting study drug; baseline corrected for heart rate (QTc) ≥Grade 1 according to NCI CTCAE Version 4.03 criteria; or abnormalities on baseline 12-lead that are considered clinically significant per the investigator.
  13. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug.
  14. Participants with >ULN, or and/or ALT >1.5 X ULN concomitant with alkaline phosphatase >2.5 X ULN cannot be allocated to Cohort D (MLN1117+docetaxel) in Part 1 and are not eligible for Part 2 if they are also EBV negative.

Part 2 only

  1. Has prior treatment with any of the following:
  • An Aurora A-targeted agent (not eligible for randomization in Cohorts B, C, or D, but eligible for Cohort A if EBV positive).
  • A docetaxel- or paclitaxel-containing chemotherapy regimen (not eligible for randomization in Cohorts B, C, or D, but eligible for Cohort A if EBV positive).
  • A spleen tyrosine kinase (SYK) inhibitor (MLN1117+TAK-659 arm only).
  • A phosphoinositide 3-kinase (PI3K) or serine/threonine kinase, also known as protein kinase B or PKB (AKT) inhibitor.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    MLN1117 300 mg + Alisertib

    MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.

    Drug: MLN1117 · Drug: Alisertib

  • Experimental
    MLN1117 600 mg + Alisertib

    MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.

    Drug: MLN1117 · Drug: Alisertib

  • Experimental
    MLN1117 300 mg + Paclitaxel

    MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m\^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.

    Drug: MLN1117 · Drug: Paclitaxel

  • Experimental
    MLN1117 600 mg + Paclitaxel

    MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m\^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.

    Drug: MLN1117 · Drug: Paclitaxel

  • Experimental
    MLN1117 300 mg + TAK-659

    MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 \[NCT02000934\]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.

    Drug: MLN1117 · Drug: TAK-659 · Drug: Docetaxel

  • Experimental
    MLN1117 200 mg + Docetaxel

    MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m\^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.

    Drug: MLN1117 · Drug: Docetaxel

  • Experimental
    MLN1117 300 mg + Docetaxel

    MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m\^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.

    Drug: MLN1117

Interventions

  • MLN1117 Tablets

    Also known as: TAK-117

  • TAK-659 Tablets

  • Alisertib Tablets

    Also known as: MLN8237

  • Paclitaxel intravenous infusion

  • Docetaxel intravenous infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1

    Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of following considered related to any of treatment by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; ≥ Grade 3 neutropenia with coincident fever or infection; Grade 4 thrombocytopenia for \>7 days; Grade 3 thrombocytopenia with clinically significant bleeding; Platelet count \<10,000/mm\^3 at any time; Delay in initiation of subsequent therapy cycle by \>7 days due to treatment-related toxicity; ≥Grade 3 nonhematological toxicity except Grade 3 arthralgia/myalgia, fatigue that lasts \<1 month, diarrhea, fasting hyperglycemia lasting ≤14 days, rash lasting ≤7 days and any other Grade 3 nonhematological toxicity that could be safely, reliably controlled to ≤Grade 1 with appropriate treatment; ≥ Grade 2 nonhematologic toxicities that are considered by investigator to be related to study drugs and dose-limiting.

    Time frame: Up to Cycle 1 (28 days for MLN1117+TAK-659, MLN1117+Alisertib, MLN1117+Paclitaxel or 21 days for MLN1117+Docetaxel)

  2. Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

  3. Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. There are 5 grades of the CTCAE; "grade" refers to severity. Grade 5 is the most severe, grade 1 is the least severe. As per version 4.0 of the CTCAE, Grade 3 = AE with severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 = AE with life-threatening consequences; urgent intervention indicated and Grade 5 = Death related to AE.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

  4. Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

  5. Number of Participants With at Least 1 Dose Modification Due to AE in Part 1

    A decision regarding which study drug requires dose modification is dependent upon the toxicity, its onset, and time course. The causal relationship of each AE should will be assessed in relation to MLN1117 and to the combination agent in each cohort so that dose modifications can be made accordingly. Intrapatient dose reductions of MLN1117 are not permitted during Part 1 Cycle 1 unless the participant experiences a DLT attributed to MLN1117. Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels. When a dose reduction of MLN1117 occurs, the MLN1117 dose will be reduced to the next lower dose that has been established as a safe dose during dose escalation (Part 1).

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

  6. Overall Response Rate in Part 2

    Overall response is defined as complete response (CR) plus partial response (PR) according to Response Evaluation Criteria in Solid tumors (RECIST) version 1.1 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

Secondary outcomes

  1. Number of Participants With at Least 1 TEAE and Serious TEAE in Part 1 and 2

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

  2. Number of Participants With Dose Delays, Dose Reductions, and Dose Interruptions Due To AE in Part 1 and 2

    Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)

  3. Progression-Free Survival (PFS) Based on RECIST Criteria V 1.1 Assessment in Part 2

    PFS is defined as the time from the date of randomization to the date of first documentation of Progressive disease (PD) or death due to any cause, whichever occurs first. PD is defined as an increase of \>=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest).

    Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

  4. Percentage of Participants With Disease Control Based on RECIST Criteria V 1.1 Assessment in Part 2

    Disease control rate is defined as the percentage of participants with complete response (CR) + Partial response (PR) + stable disease (SD) according to RECIST version 1.1 criteria. CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as not qualifying for CR, PR, or PD.

    Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

  5. Duration of Response (DOR) Based on RECIST Criteria V 1.1 Assessment in Part 2

    DOR is defined as the time from the date of first documentation of a response to the date of first documentation of PD according to RECIST version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

    Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

  6. Time to Disease Progression (TTP) Based on RECIST Criteria V 1.1 Assessment in Part 2

    TTP is defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

    Time frame: Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

  7. Overall Survival (OS) Based on RECIST Criteria V 1.1 Assessment

    OS is defined as the time from the date of randomization to the date of death.

    Time frame: From randomization up to end of Part 2, then every 12 weeks until participant death or until 1 year after the last dose of study drug, whichever occurs first (up to 336 days)

  8. Plasma Concentration of MLN1117-1003

    Time frame: MLN1117 300 mg + Alisertib arms: Cycle 1 Day 3; MLN1117 300 mg + Paclitaxel arms and MLN1117 200 mg + Docetaxel arms: Cycle 1 Day 2; MLN1117 300 mg + TAK-659 arm: Cycle 1 Days 1 and 17

07

Results

Posted Sep 20, 2019
Limitations and caveats
Due to the early termination of the study, the pharmacokinetic data collected was not processed further. Therefore, the planned secondary endpoints of PK summary statistics are not reported.

Participant flow

Participants took part in the study at 3 investigative sites in Spain and the United States from 15 October 2015 to 18 January 2017.

Participant flow — Overall Study
MilestoneMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelPart 2
Started46367240
Completed00110110
Not completed46257130
Withdrew: Death24222120
Withdrew: Study terminated by sponsor11022000
Withdrew: Withdrawal by subject11012000
Withdrew: Reason not specified00001010

Outcome measures

PrimaryNumber of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1

Toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. DLT defined as any of following considered related to any of treatment by investigator: Grade 4 neutropenia (absolute neutrophil count \<500 cells/mm\^3) for \>7 days; ≥ Grade 3 neutropenia with coincident fever or infection; Grade 4 thrombocytopenia for \>7 days; Grade 3 thrombocytopenia with clinically significant bleeding; Platelet count \<10,000/mm\^3 at any time; Delay in initiation of subsequent therapy cycle by \>7 days due to treatment-related toxicity; ≥Grade 3 nonhematological toxicity except Grade 3 arthralgia/myalgia, fatigue that lasts \<1 month, diarrhea, fasting hyperglycemia lasting ≤14 days, rash lasting ≤7 days and any other Grade 3 nonhematological toxicity that could be safely, reliably controlled to ≤Grade 1 with appropriate treatment; ≥ Grade 2 nonhematologic toxicities that are considered by investigator to be related to study drugs and dose-limiting.

Time frame:
Up to Cycle 1 (28 days for MLN1117+TAK-659, MLN1117+Alisertib, MLN1117+Paclitaxel or 21 days for MLN1117+Docetaxel)
Reported as:
Number · participants
Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 1
participantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT) in Part 10100101
PrimaryNumber of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A Serious Adverse Event (SAE) A serious is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Reported as:
Number · participants
Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 1
participantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE) in Part 14636724
PrimaryNumber of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. There are 5 grades of the CTCAE; "grade" refers to severity. Grade 5 is the most severe, grade 1 is the least severe. As per version 4.0 of the CTCAE, Grade 3 = AE with severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 = AE with life-threatening consequences; urgent intervention indicated and Grade 5 = Death related to AE.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Reported as:
Number · participants
Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 1
participantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
Number of Participants With at Least 1 ≥ Grade 3 TEAE in Part 14422624
PrimaryNumber of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Reported as:
Number · participants
Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 1
participantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
Number of Participants With at Least 1 Treatment-Emergent Serious Adverse Event (SAE) in Part 12312524
PrimaryNumber of Participants With at Least 1 Dose Modification Due to AE in Part 1

A decision regarding which study drug requires dose modification is dependent upon the toxicity, its onset, and time course. The causal relationship of each AE should will be assessed in relation to MLN1117 and to the combination agent in each cohort so that dose modifications can be made accordingly. Intrapatient dose reductions of MLN1117 are not permitted during Part 1 Cycle 1 unless the participant experiences a DLT attributed to MLN1117. Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels. When a dose reduction of MLN1117 occurs, the MLN1117 dose will be reduced to the next lower dose that has been established as a safe dose during dose escalation (Part 1).

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Reported as:
Number · participants
Number of Participants With at Least 1 Dose Modification Due to AE in Part 1
participantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
Number of Participants With at Least 1 Dose Modification Due to AE in Part 10110401
PrimaryOverall Response Rate in Part 2

Overall response is defined as complete response (CR) plus partial response (PR) according to Response Evaluation Criteria in Solid tumors (RECIST) version 1.1 criteria. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

No measurements were reported for this outcome.

SecondaryNumber of Participants With at Least 1 TEAE and Serious TEAE in Part 1 and 2

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; or a medically important event. TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Reported as:
Number · participants
Number of Participants With at Least 1 TEAE and Serious TEAE in Part 1 and 2
participantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelPart 2
AE4636724—
SAE2312524—
SecondaryNumber of Participants With Dose Delays, Dose Reductions, and Dose Interruptions Due To AE in Part 1 and 2

Per dose modification guidelines, participants who have the study drug held because of treatment related or possibly related AEs may resume study drug treatment after resolution of the AE but may either maintain the same dose level or have doses of study drug reduced (dose reduction) by at least 1 dose level and if needed, by 2 dose levels.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 366 days)
Reported as:
Count of participants · Participants
Number of Participants With Dose Delays, Dose Reductions, and Dose Interruptions Due To AE in Part 1 and 2
ParticipantsMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelPart 2
Dose delay due to AE0000100—
Dose reduction due to AE0110401—
Dose interruption due to AE0010000—
SecondaryProgression-Free Survival (PFS) Based on RECIST Criteria V 1.1 Assessment in Part 2

PFS is defined as the time from the date of randomization to the date of first documentation of Progressive disease (PD) or death due to any cause, whichever occurs first. PD is defined as an increase of \>=20% from the nadir (or baseline, if it represents the point at which the sum of target disease was lowest).

Time frame:
Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Disease Control Based on RECIST Criteria V 1.1 Assessment in Part 2

Disease control rate is defined as the percentage of participants with complete response (CR) + Partial response (PR) + stable disease (SD) according to RECIST version 1.1 criteria. CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as not qualifying for CR, PR, or PD.

Time frame:
Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR) Based on RECIST Criteria V 1.1 Assessment in Part 2

DOR is defined as the time from the date of first documentation of a response to the date of first documentation of PD according to RECIST version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

Time frame:
Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

No measurements were reported for this outcome.

SecondaryTime to Disease Progression (TTP) Based on RECIST Criteria V 1.1 Assessment in Part 2

TTP is defined as the time from the date of randomization to the date of first documentation of PD. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

Time frame:
Days 25-28 for MLN1117+TAK-659, MLN1117+Alisertib, and MLN1117+Paclitaxel and Days 18-21 for MLN1117+Docetaxel of Cycles 2, 4, 6; every other cycle until study discontinuation due to disease progression, unacceptable toxicity, or death (up to 336 days)

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) Based on RECIST Criteria V 1.1 Assessment

OS is defined as the time from the date of randomization to the date of death.

Time frame:
From randomization up to end of Part 2, then every 12 weeks until participant death or until 1 year after the last dose of study drug, whichever occurs first (up to 336 days)

No measurements were reported for this outcome.

SecondaryPlasma Concentration of MLN1117-1003
Time frame:
MLN1117 300 mg + Alisertib arms: Cycle 1 Day 3; MLN1117 300 mg + Paclitaxel arms and MLN1117 200 mg + Docetaxel arms: Cycle 1 Day 2; MLN1117 300 mg + TAK-659 arm: Cycle 1 Days 1 and 17
Reported as:
Mean · ng/mL
Plasma Concentration of MLN1117-1003
ng/mLMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
Day 1: PredoseNA ± NANA ± NANA ± NANA ± NA0.00 ± 0.000NA ± NANA ± NA
Day 1: 0.5 Hour PostdoseNA ± NANA ± NANA ± NANA ± NA675.04 ± 816.641NA ± NANA ± NA
Day 1: 1 Hour PostdoseNA ± NANA ± NANA ± NANA ± NA2171.00 ± 1840.041NA ± NANA ± NA
Day 1: 2 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA3054.14 ± 1811.084NA ± NANA ± NA
Day 1: 3 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA3315.29 ± 1521.130NA ± NANA ± NA
Day 1: 4 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA3164.71 ± 1522.096NA ± NANA ± NA
Day 1: 6 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA2726.71 ± 1259.976NA ± NANA ± NA
Day 1: 8 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA2466.29 ± 1112.350NA ± NANA ± NA
Day 1: 24 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA1045.17 ± 642.781NA ± NANA ± NA
Day 2: PredoseNA ± NANA ± NA0.00 ± 0.0000.00 ± 0.000NA ± NA0.00 ± 0.0000.00 ± 0.000
Day 2: 0.5 Hour PostdoseNA ± NANA ± NA1762.00 ± 1295.7281701.17 ± 1407.015NA ± NA3240.00 ± 1230.3661333.05 ± 1970.336
Day 2: 1 Hour PostdoseNA ± NANA ± NA3840.00 ± 747.1953261.83 ± 2879.952NA ± NA3165.00 ± 1859.6911554.00 ± 2042.092
Day 2: 2 Hours PostdoseNA ± NANA ± NA4066.67 ± 322.5423934.00 ± 3419.860NA ± NA4615.00 ± 4433.5601456.23 ± 1577.178
Day 2: 3 Hours PostdoseNA ± NANA ± NA3653.33 ± 325.6283753.50 ± 3324.071NA ± NA4355.00 ± 4362.8491598.75 ± 1269.397
Day 2: 4 Hours PostdoseNA ± NANA ± NA3206.67 ± 256.9703994.67 ± 3191.500NA ± NA3725.00 ± 3542.6051475.75 ± 1062.242
Day 2: 6 Hours PostdoseNA ± NANA ± NA2720.00 ± 10.0004311.67 ± 2752.595NA ± NA3085.00 ± 2920.3511417.75 ± 907.208
Day 2: 8 Hours PostdoseNA ± NANA ± NA2536.67 ± 87.3693246.00 ± 2026.285NA ± NA3025.00 ± 2807.2141443.25 ± 992.241
Day 2: 24 Hours PostdoseNA ± NANA ± NA592.67 ± 38.5271279.83 ± 1238.550NA ± NA717.00 ± 668.923420.80 ± 477.731
Day 3: Predose2177.50 ± 1453.7173178.82 ± 2696.065NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 0.5 Hour Postdose3225.00 ± 693.2294554.80 ± 3431.547NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 1 Hour Postdose5010.00 ± 1376.5905070.60 ± 3278.807NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 2 Hours Postdose5007.50 ± 1192.3476235.80 ± 4139.804NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 3 Hours Postdose4815.00 ± 810.5355650.00 ± 3995.103NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 4 Hours Postdose4797.50 ± 1240.2254719.20 ± 3100.983NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 6 Hours Postdose4777.50 ± 1753.0244501.80 ± 2904.730NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 8 Hours Postdose4320.00 ± 1862.0784354.80 ± 2836.444NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 3: 24 Hours Postdose2217.33 ± 1604.2452357.42 ± 1806.031NA ± NANA ± NANA ± NANA ± NANA ± NA
Day 17: PredoseNA ± NANA ± NANA ± NANA ± NA978.33 ± 1519.070NA ± NANA ± NA
Day 17: 0.5 Hour PostdoseNA ± NANA ± NANA ± NANA ± NA2893.67 ± 1738.859NA ± NANA ± NA
Day 17: 1 Hour PostdoseNA ± NANA ± NANA ± NANA ± NA5596.67 ± 387.599NA ± NANA ± NA
Day 17: 2 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA5583.33 ± 1146.575NA ± NANA ± NA
Day 17: 3 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA5116.67 ± 1608.426NA ± NANA ± NA
Day 17: 4 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA5066.67 ± 2009.784NA ± NANA ± NA
Day 17: 6 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA4293.33 ± 1654.398NA ± NANA ± NA
Day 17: 8 Hours PostdoseNA ± NANA ± NANA ± NANA ± NA4330.00 ± 2606.971NA ± NANA ± NA

Adverse events

Collected over From first dose of study drug through 30 days after the last dose of study drug. Related SAEs could be reported at any time after discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MLN1117 300 mg + Alisertib0/4 (0%)2/4 (50%)4/4 (100%)
MLN1117 600 mg + Alisertib0/6 (0%)3/6 (50%)6/6 (100%)
MLN1117 300 mg + Paclitaxel1/3 (33.3%)1/3 (33.3%)3/3 (100%)
MLN1117 600 mg + Paclitaxel1/6 (16.7%)2/6 (33.3%)6/6 (100%)
MLN1117 300 mg + TAK-6591/7 (14.3%)5/7 (71.4%)7/7 (100%)
MLN1117 200 mg + Docetaxel1/2 (50%)2/2 (100%)2/2 (100%)
MLN1117 300 mg + Docetaxel2/4 (50%)4/4 (100%)4/4 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
SepsisInfections and infestations0/40/60/30/61/70/22/4
PneumoniaInfections and infestations0/40/60/30/60/71/20/4
Febrile neutropeniaBlood and lymphatic system disorders0/40/60/30/60/71/22/4
Liver function test increasedInvestigations0/40/60/30/60/71/20/4
Neutrophil count decreasedInvestigations0/40/60/30/60/71/20/4
Rectal haemorrhageGastrointestinal disorders0/40/61/30/60/70/20/4
Neuroendocrine carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/61/30/60/70/20/4
Abdominal painGastrointestinal disorders0/40/60/30/61/70/21/4
Small intestinal obstructionGastrointestinal disorders0/40/60/30/60/70/21/4
Upper gastrointestinal haemorrhageGastrointestinal disorders1/40/60/30/60/70/20/4
Most frequent other events
Showing 10 of 160
Most frequent other events
EventMLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + Docetaxel
NeutropeniaBlood and lymphatic system disorders2/44/61/32/60/71/24/4
MyalgiaMusculoskeletal and connective tissue disorders0/41/61/30/61/72/20/4
FatigueGeneral disorders3/43/61/30/61/71/22/4
NauseaGastrointestinal disorders0/42/62/32/64/71/21/4
Abdominal painGastrointestinal disorders1/44/61/32/60/70/20/4
ConstipationGastrointestinal disorders2/40/62/30/61/70/21/4
Decreased appetiteMetabolism and nutrition disorders0/44/60/31/62/71/21/4
Oedema peripheralGeneral disorders1/41/62/30/61/70/20/4
Night sweatsSkin and subcutaneous tissue disorders0/41/62/31/62/70/20/4
VomitingGastrointestinal disorders2/42/61/33/64/70/20/4

Baseline characteristics

Safety population is defined as all participants who received at least 1 dose of any study drug. Participants are analyzed according to the treatment actually received.

Age, Continuous
Age, Continuous(years)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
Mean61.5 ± 7.9459.0 ± 4.8665.3 ± 13.2862.2 ± 11.8262.3 ± 9.1665.5 ± 4.9562.3 ± 9.9562.0 ± 8.61
Sex: Female, Male
Sex: Female, Male(Participants)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
Female333572225
Male13010027
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
Hispanic or Latino00011013
Not Hispanic or Latino463562329
Not Reported00000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
White442661427
Black or African American01101104
Asian01000001
Region of Enrollment
Region of Enrollment(participants)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
United States453362427
Spain01031005
Height
Height(cm)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
Mean162.90 ± 14.178165.50 ± 10.145159.80 ± 4.513162.83 ± 15.108158.76 ± 6.662154.95 ± 7.142166.25 ± 16.674162.07 ± 10.939
Weight
Weight(kg)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
Mean77.75 ± 15.31471.63 ± 19.72574.07 ± 12.75682.38 ± 25.47465.53 ± 13.04675.45 ± 43.91168.28 ± 21.40373.13 ± 19.400
Body Surface Area
Body Surface Area(m^2)MLN1117 300 mg + AlisertibMLN1117 600 mg + AlisertibMLN1117 300 mg + PaclitaxelMLN1117 600 mg + PaclitaxelMLN1117 300 mg + TAK-659MLN1117 200 mg + DocetaxelMLN1117 300 mg + DocetaxelTotal
Mean1.825 ± 0.28141.802 ± 0.28631.809 ± 0.16381.917 ± 0.34961.694 ± 0.17901.768 ± 0.57691.767 ± 0.37341.796 ± 0.2796
08

Study locations

6 sites
  • Lake Success, New York, United States
  • New York, New York, United States
  • Philadelphia, Pennsylvania, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Barcelona, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Feb 2017, 16 months.

Results were first posted in Sep 2019, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 16, 2015
StartActual
Oct 15, 2015
Primary completionActual
Feb 17, 2017
CompletionActual
Feb 17, 2017
Results first posted
Sep 20, 2019
Last update
Sep 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02551055
Responsible party
Sponsor
First posted
Sep 16, 2015
Start date
Oct 15, 2015
Primary completion
Feb 17, 2017
Completion
Feb 17, 2017
Results posted
Sep 20, 2019
Last update
Sep 20, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serabelisib

Start the discussion